CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 144 enrolled
Drug / intervention
Selective Screeningother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02082483
NCT02082483N/ACompleted
CompareCT.gov

Pilot Study to Determine Feasibility of a Randomized Trial of Screening for Coronary Artery Disease in Kidney Transplant Candidates

University of British Columbia·interventional·Posted Mar 10, 2014·Updated May 13, 2024

In Brief

A clinical study evaluating Selective Screening for End Stage Renal Disease and Coronary Artery Disease. Completed, enrolled 144 participants across 6 sites.

Detailed Summary

Kidney transplant candidates are at very high risk for coronary artery disease (CAD). The optimal strategy to monitor and maintain the cardiac fitness of patients awaiting kidney transplantation is unknown. Currently patients undergo annual testing; however, screening for CAD may increase morbidity and mortality by: 1. exposing patients to the risk of angiography and revascularization procedures 2. delaying or excluding patients from life saving transplantation. Before proceeding with a definitive study to determine whether screening is necessary, feasibility will be determined in this pilot study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease, Coronary Artery Disease
CountriesCanada
CollaboratorsCanadian Institutes of Health Research (CIHR)

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 10, 2014
Enrollment StartNov 1, 2014
Primary CompletionFeb 1, 2019
Study CompletionJul 31, 2019
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.3 years ago

Interventions

Selective Screeningother

Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.